Pfizer’s Remoxy Clears Manufacturing Hurdle, Still Needs BE, Abuse-Potential Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
Extended-release oxycodone product has potential for broader abuse-deterrent claims than OxyContin; Pfizer expects to resubmit Remoxy to FDA by mid-2015.